ASX ANNOUNCEMENT INVION RECEIVES >$0.5M R&D TAX INCENTIVE REBATE MELBOURNE (AUSTRALIA) 19 November 2026: Invion Limited (ASX: IVX) ("Invion" or the "Company"), a clinical-stage life sciences company developing its next-generation photodynamic therapy platform (NGPDT) called Photosoft™, is pleased...
Invion Receives $0.5m R&D Tax Incentive Rebate
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The funding is part of Invion's strategy to finance its clinical pipeline, including upcoming trials for skin cancer and anogenital indications. The announcement was approved by Invion’s Board of Directors and highlights the importance of non-dilutive funding for the company's research efforts.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Earlier from Invion
- Change of Director's Interest Notice - Thian Chew
- Notification of cessation of securities - IVX
- IVX Director Appointment/Resignation & New Company Secretary
- Appendix 4C and Quarterly Activities Report - September 2026
- Notice of Annual General Meeting/Proxy Form
Follow Invion into a list and get an email when it puts out news.
Follow Invion